Last reviewed · How we verify
NCT04736381: MERRLIN
Impact of the Microbiota on the Likelihood of Renal Graft Rejection
trial testing Belatacept Injection [Nulojix] in Kidney Transplant Rejection in 70 participants. Currently enrolling.
7 January 2027
Quick facts
| Lead sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 7 October 2021 |
| Primary completion | 7 January 2027 |
| Estimated completion | 7 January 2027 |
| Sites | 9 locations across France |
Drugs / interventions tested
- Belatacept Injection [Nulojix] — full drug profile →
Conditions studied
- Kidney Transplant Rejection — all drugs for Kidney Transplant Rejection →
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France — full company profile →
Who can join
Adults 18 to 70, any sex, with Kidney Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Identification of a bacterial signature in the blood or stool that may be associated with acute rejection in patients treated with Nulojix during their first year of transplant.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04736381
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplant Rejection
Currently open trials in the same condition.
- NCT07412470 — A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati · Phase 2, PHASE3 · recruiting
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT06564649 — PROACT Pilot Trial · active not recruiting
- NCT07006532 — Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab · NA · recruiting
- NCT07275541 — Platelet Aggregation in the Diagnosis of Acute Graft Rejection · recruiting
Other Institut National de la Santé Et de la Recherche Médicale, France trials
Trials by the same sponsor.
- NCT07311213 — GENES AND AUTISM - IPSC · NA · not yet recruiting
- NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting
- NCT06906042 — Multimodal Cardiovascular and Hepatic Population Imaging · recruiting
- NCT06951035 — Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke · NA · not yet recruiting
- NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04736381 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut National de la Santé Et de la Recherche Médicale, France
- Last refreshed: 10 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04736381.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing